Stoke Therapeutics Inc. closed its planned IPO on the Nasdaq Global Select Market, raising gross proceeds of about $163.3 million.

The company sold 9,074,776 shares at $18 apiece, including 1,183,666 shares that were sold upon full exercise of the underwriters' option.

The Bedford, Mass.-based company started trading on the Nasdaq under the ticker STOK on June 19.

Stoke Therapeutics has said earlier that it would use the proceeds for a phase 3 clinical development of its lead product candidate STK-001 to treat Dravet syndrome, a type of epilepsy with seizures often triggered by high body temperatures or fever. The funds would also go toward conducting preclinical studies for other product candidates.

J.P. Morgan Securities LLC, Cowen and Co. LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers, while Canaccord Genuity LLC acted as lead manager for the offering.